Evotec has appointed Tim Tasker as executive vice president of clinical development and a member of the executive committee, the Hamburg, Germany-based drug-discovery firm said last week.
Tasker will join Evotec July 11. Tasker most recently served as vice president of global clinical units, clinical pharmacology, and discovery medicine at GlaxoSmithKline. He holds a BA in physiological sciences from the University of Oxford and an MD from London University.
Daniel Bradbury and John Stuelpnagel have been reelected to Illumina's board of directors, following the company's annual meeting of stockholders held in San Diego two weeks ago. Bradbury serves as chief operating officer of Amylin Pharmaceuticals, and Stuelpnagel is senior vice president and COO of Illumina.
Ibidi has launched a new chemotaxis assay based on the company's u-Slides microscopy carriers, ibidi said last week.
The assay allows real-time imaging of fast-moving cells during incubation with a chemoattractant, ibidi said.
The development was carried out in collaboration with the Max Planck Institute for Biochemistry in Martinsried, Germany, and first results from experiments using the assay were published in the May issue of American Biotechnology Laboratory. Ibidi said it plans to develop parallel assays for following slower cell types, such as cancer cells and primary cells.